Regulatory changes along a drug’s lifecycle should ensure that the health benefits of pharmaceuticals, which have a large ecological footprint, do not cost the environment. Dorothea Baltruks, Research Associate at the Centre for Planetary Health Policy, outlines how forthcoming EU pharmaceutical legislation could pave the way to solutions.
We have 27 years left to transform the EU into a climate-neutral continent in order to keep the ecological catastrophes that the climate crisis brings at a manageable level – to find solutions for every flight taken, every car driven and every medical treatment undergone in the EU. Other sectors are already on the way to reducing their emissions and have received much public and political attention. Yet the pharmaceutical sector is just starting that journey; one that will be impacted substantially by consequences of the climate crisis – from heatwaves to new infectious diseases, to longer hay fever seasons and new allergies.1
Pharma’s climate footprint
Numbers first: the health system produces 4.7 percent of the EU’s greenhouse gas emissions – more than twice as much as aviation. Seventy five percent of EU health systems’ emissions are released indirectly along the supply chain of pharmaceuticals, medical and other products.2 A study found that pharmaceuticals and other chemical products are responsible for 40 percent of the Dutch healthcare system’s greenhouse gas emissions and about 80 percent of its share of material extraction.3
Hence, every country that looks at decarbonising its health sector – and all EU Member States must – will quickly look at the pharmaceutical industry. In addition, the number of active substances detected in the environment has been increasing with unknown consequences for ecosystems and the accumulation of substances in food chains.4
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
Together with a legal expert from the Bucerius Law School Hamburg, we looked at the legal and political frameworks that could enable the German pharmaceutical sector to become more sustainable.5 We considered the whole lifecycle of a drug, as environmental impacts arise at every stage of the process from development and production to administration and disposal.
Giving environmental risk assessments teeth
Since 2005, the authorisation of a human pharmaceutical product requires an environmental risk assessment (ERA). The problem is that if potentially undesirable effects on the environment are identified, this remains largely inconsequential for the authorisation. Interestingly, this is not the case for veterinary medicines, where the authorisation can actually be refused if the risk is not adequately mitigated. The ERA therefore needs teeth – which does not mean it should be a barrier to the authorisation of new medicines – but it should require pharmaceutical companies to minimise harmful effects on the environment, which indirectly also harm our health.
the ERA… has provided data on the environmental impacts of pharmaceuticals; data that is often missing for drugs that were authorised before [its] introduction”
However, the ERA is not completely worthless. Rather, it has provided data on the environmental impacts of pharmaceuticals; data that is often missing for drugs that were authorised before the introduction of ERA. Therefore, another question is how we can obtain reliable, transparent information on older drugs. There is still a huge gap in publicly available data for most drugs sold in the EU, which is the first barrier to assessing the status quo.
The leaked draft of the European pharmaceutical package is promising on this point as it states that marketing authorisation may be refused if the ERA is not completed or risk mitigation measures are insufficient, and that an ERA programme should be set up for medicines that were authorised before the introduction of the ERA.6
An important but often opaque consideration is the supply chains in non-EU countries, which play a predominant role especially in the production of generic drugs and antibiotics. Germany’s new Act on Corporate Due Diligence Obligations in Supply Chains (LkSG) is a first step to holding companies to account for human rights violations and soil, water and air pollution. It does not include impacts of the climate and biodiversity crises, though, and only applies to a company’s own operations and direct suppliers.
The European Commission’s draft Corporate Sustainability Due Diligence Directive would go further and actually require large companies to bring their strategies in line with the 1.5°C-limit and be applied to the whole supply chain.7 We would also argue that the pharmaceutical sector should be identified as a “high-impact” sector, given its significant ecological impact.
The obvious question is: if the EU introduces stricter regulations for pharmaceuticals, won’t manufacturers be further deterred from producing medicines in the EU?
In terms of medicines sold in the EU, that should not be a major concern as the continent will remain a major market for pharmaceutical companies, even if the regulatory requirements are strengthened. For the production of pharmaceuticals sold elsewhere in the world, this may be true to a degree, although newer drugs with high margins and promising potential will still be developed in the EU, given the rich research and development environment here.
Other countries are looking at environmental impacts, too. The National Health Service in England has set out a clear roadmap towards climate neutrality including reporting emission reduction obligations for its suppliers. Pharmaceutical companies know that they must address their ecological impact and some have already set out ambitious plans and targets to play their part.
Information, education, efficacy
Ecological aspects should also be integrated into the training and further education of other healthcare professionals – such as pharmacists – so that they can competently advise customers. Advising on more environmentally-friendly alternatives to most medicines is difficult, given that the required information is often missing. The Stockholm region in Sweden attempted this by developing a “Wise List” of medicines between 2017 and 2021, which enables physicians to select the least environmentally harmful product from those with equivalent efficacy.8
“Prominent examples of climate-unfriendly medicinal products are…anaesthetic gases like desflurane…and metered dose inhalers”
The most prominent examples of climate-unfriendly medicinal products are the focus of medical associations trying to reduce their use: anaesthetic gases like desflurane (a 2,500 times more potent greenhouse gas than CO2, which is already being phased out in England)9 and metered dose inhalers, which the German College of General Practitioners and Family Physicians advises be replaced where possible with more climate-friendly dry powder inhalers.10
Is the journey towards a pharmaceutical sector that operates within the planetary boundaries going to be easy? Of course not. The required actions will be complicated, maybe even controversial. But so is the required transformational process in every sector. Let’s remember: the status quo or too little action will lead us into multiple ecological catastrophes that are a much greater threat to our economies, health and societies than any legislative change proposed in our policy brief could ever be.
About the author
Dorothea Baltruks is a Research Associate at the Centre for Planetary Health Policy (CPHP) where she focuses on the transformation of the German health system towards climate resilience and sustainability. After studying international and social policy at King’s College London and the London School of Economics and Political Science, Dorothea worked for a health consultancy in the UK and the European Social Network. Later, she led the research policy, global and data analysis portfolios at the Council of Deans of Health, which represents the UK universities’ health faculties. Before joining CPHP, she advised the Green Party’s health spokesperson in the Bavarian state parliament.
References
van Daalen K, et al. 2022. The 2022 Europe report of the Lancet Countdown on health and climate change: Towards a climate resilient future. The Lancet Public Health. 7(11): 942-965.
Steenmeijer M, et al. The environmental impact of the Dutch health-care sector beyond climate change: an input-output analysis. Lancet Planetary Health. 2022; 6: 949-57.
Gildemeister D, et al. Improving environmental protection in EU pharmaceutical legislation. 2022. Dessau-Roßlau: German Environment Agency.
Baltruks D, Sowa M, Voss M. Strengthening sustainability in the pharmaceutical sector. [Internet] Berlin: Centre for Planetary Health Policy. 2023. Available from: https://cphp-berlin.de.
European Commission. European Pharmaceutical Strategy – European Commission (draft) Pharmaceutical package.
European Commission. 2022. Proposal for a Directive of the European Parliament and of the Council on corporate due diligence with regard to sustainability and amending Directive (EU) 2019/1937.
Stockholm Region (n.d.). Information on environmental effects of medicinal products. [Internet] Janusinfo Region Stockholm. [cited 23Apr]. Available from: https://janusinfo.se/beslutsstod/lakemedelochmiljo/pharmaceuticalsandenvironment.4.7b57ecc216251fae47487d9a.html.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.